The vaccine market has long been dominated by the Big 3--Sanofi ($SNY), Merck ($MRK) and GlaxoSmithKline ($GSK)--with Pfizer ($PFE) and Novartis ($NVS) trailing the trio on the list of revenue-generators. But things are changing at the top. The "go big or go home" mentality has sent Novartis packing, with the Swiss company selling GSK most of its vaccines unit earlier this year as it made moves to exit the space. Pfizer, on the other hand, is scouting for ways to bulk up, earlier this month listing AstraZeneca's ($AZN) vaccine assets among the benefits of a potential merger.
For now, though, behind Pfizer's market-leading Prevnar 13, it's jabs from the leading triumvirate that bring in the bulk of vaccine sales. Merck, in particular, took four of the 10 top-selling spots, with Glaxo and Sanofi nabbing two apiece.
But like the list of vaccine heavyweights, the list of top-performing products has seen some shuffling as of late. Take a look at our table of those that enjoyed the most top-line success in 2013--assembled using data from EvaluatePharma--and if you'd like, compare it with the first-half data from the year prior.
And, as always, give us a shout if you've got something to say about it. -- Carly Helfand (email | Twitter)
|1. Prevnar 13||$4.048 billion||Pneumococcal infection|
|2. Gardasil||$2.167 billion||Human papillomavirus (HPV)|
|3. PENTAct-HIB||$1.525 billion||Diphtheria, pertussis/whooping cough; tetanus; polio; Haemophilus influenzae type B|
|4. Fluzone/Vaxigrip||$1.396 billion||Influenza|
|5. Varivax||$1.377 billion||Varicella virus|
|6. Pediarix||$1.349 billion||Diphtheria; tetanus; pertussis/whooping cough; hepatitis B; polio|
|7. Hepatitis vaccine franchise||$984 million||Hepatitis A; hepatitis B|
|8. Zostavax||$826 million||Shingles; herpes|
|9. RotaTeq||$691 million||Rotaviral gastroenteritis|
|10. Pneumovax||$653 million||Pneumococcal infection|